Propranolol

The reviewed IR tablet label covers hypertension, coronary angina, ventricular-rate control in atrial fibrillation, reduced cardiovascular mortality after a clinically stable myocardial infarction, migraine prevention, essential tremor, symptomatic hypertrophic subaortic stenosis and pheochromocytoma as an adjunct to alpha blockade. It does not treat hypertensive emergencies or an active migraine attack.

Inderal LA is labeled for hypertension, coronary angina, migraine prevention and hypertrophic subaortic stenosis. InnoPran XL is labeled for hypertension only. Do not transfer all IR indications to either extended-release product.

Hemangeol treats proliferating infantile hemangioma requiring systemic therapy. Initiate at age 5 weeks to 5 months using its own weight-based oral solution schedule. Portal-hypertension regimens and other off-label uses are outside this label-based profile.

Individualize response and tolerability. The following are label regimens, not interchangeable maximum doses. Divided daily doses must remain divided.

Inderal LA is not a simple mg-for-mg substitute for divided IR dosing. Blood levels differ; retitrate and assess response near the end of 24 hours. The label has not studied food effects.

Start 80 mg once daily at bedtime and titrate to 120 mg if needed. Doses above 120 mg provide no additional blood-pressure effect. Take consistently either with food or on an empty stomach. Full blood-pressure response usually takes 2–3 weeks; this is a distinct release profile, not an IR dosing schedule.

For the 4.28 mg/mL hydrochloride solution, doses below are mL/kg PER DOSE, twice daily at least 9 hours apart. Reassess weight and readjust the prescribed mL dose periodically. Maintain the final regimen for 6 months; recurrence may warrant a clinician-directed restart.

The current Hemangeol label pairs its volume instructions with parenthetical mg/kg values that are not consistently reconciled with the stated hydrochloride/base concentration. This profile preserves the explicit labeled mL/kg schedule and does not supply a recalculated mg/kg regimen. Confirm the actual prescribed mL dose and concentration with the treating specialist/pharmacist; this discrepancy remains a source-review question.

Give Hemangeol during or immediately after a feeding; skip when not feeding or vomiting, and resume only when feeding normally under the care plan. Observe heart rate and blood pressure for 2 hours after initiation or each increase. If an infant spits up or the full dose is uncertain, do not repeat it; wait for the next scheduled dose. Use the supplied oral syringe.

Abrupt withdrawal can worsen ischemia. For chronic InnoPran XL, taper over 1–2 weeks with monitoring. IR and Inderal LA labels advise reduction over at least a few weeks; migraine discontinuation also requires a gradual plan. Do not stop on your own, including before surgery.

Adult IR/Inderal LA: cardiogenic shock, sinus bradycardia, greater-than-first-degree AV block, bronchial asthma or hypersensitivity. InnoPran XL additionally specifies decompensated heart failure and sick sinus syndrome, with a permanent-pacemaker exception for its conduction contraindication.

Hemangeol: corrected age <5 weeks after prematurity, weight <2 kg, asthma/history of bronchospasm, heart rate <80/min, greater-than-first-degree heart block, decompensated heart failure, blood pressure <50/30 mmHg, pheochromocytoma or hypersensitivity. Its pheochromocytoma contraindication differs from adult adjunctive IR use.

The current reviewed labels place cardiac ischemia after abrupt withdrawal in their warnings sections; they do not display a separate boxed-warning section in these current SPLs. Earlier InnoPran XL labels used a box. The withdrawal risk remains clinically important regardless of presentation. Hemangeol has serious hypoglycemia warnings and a Medication Guide. Check the exact dispensed product label.

Adult reports include fatigue, dizziness, sleep/mood disturbances, GI symptoms, cold extremities, bradycardia and hypotension; bronchospasm, heart failure and severe skin/allergic reactions warrant urgent attention. InnoPran XL trials commonly reported fatigue, dizziness and constipation. Hemangeol trials commonly reported sleep disturbances, aggravated respiratory infections, diarrhea and vomiting.

Verapamil/diltiazem, digoxin and antiarrhythmics can add bradycardia, block or cardiac failure risk. Propranolol can increase propafenone exposure. Monitor closely and avoid inappropriate combinations. If clonidine is also used, its withdrawal needs a coordinated plan: the XL label advises withdrawing the beta blocker several days before clonidine, while respecting propranolol taper requirements.

CYP2D6 inhibitors such as fluoxetine/paroxetine/quinidine, CYP1A2 inhibitors such as ciprofloxacin/fluvoxamine and CYP2C19 inhibitors such as fluconazole can raise exposure: monitor heart rate and pressure. Inducers such as rifampin/phenytoin and smoking can reduce effect. Cholestyramine/colestipol can reduce levels. Medication changes may require reassessment.

Monitor prothrombin time/INR with warfarin. Alpha blockers and MAO inhibitors/tricyclic antidepressants can increase hypotension; NSAIDs can weaken antihypertensive response. IR/LA labels describe increased rizatriptan/zolmitriptan exposure; use their own product-specific interaction instructions.

Hemangeol interactions include medicines slowing cardiac conduction or changing propranolol metabolism. Corticosteroids can increase hypoglycemia risk. Review medications taken by a breastfeeding parent because milk exposure may interact with the infant’s treatment; do not stop breastfeeding or medicines without advice.

Adult IR/LA labels advise caution in renal or hepatic impairment without a fixed adjustment table. InnoPran XL specifies starting at its lowest dose, 80 mg once daily, in either impairment and monitoring marked bradycardia/hypotension. Exposure may rise in organ impairment; older adults require cautious dose selection. Propranolol is not significantly dialyzable.

Adult IR, Inderal LA and InnoPran XL safety/effectiveness are not established for pediatric use in these labels. Hemangeol is the infant-specific approved product; use its initiation window, corrected-age/weight contraindications and monitoring. Safety/effectiveness beyond age 1 year and in infants with renal/hepatic impairment are not established.

Current InnoPran XL labeling describes no identified drug-associated major-birth-defect or miscarriage signal in published studies, but fetal-growth reports vary. Near-delivery exposure warrants neonatal monitoring for bradycardia, hypoglycemia and respiratory depression. IR/LA labels also describe fetal/neonatal concerns. Propranolol enters milk; discuss maternal need and infant risk rather than assuming absence of exposure. Hemangeol is not an adult pregnancy product.

Nonselective beta blockade lowers heart rate, contractility and AV conduction and reduces responses to sympathetic stimulation. Beta2 blockade contributes to bronchospasm. Antihypertensive and antimigraine mechanisms are incompletely established; Hemangeol’s hemangioma mechanism is not fully understood.

Oral absorption is extensive, but hepatic first-pass metabolism leaves about 25% systemically available on average. Propranolol is about 90% protein-bound, crosses the brain/placenta and is metabolized through CYP2D6, CYP1A2 and CYP2C19 pathways; metabolites leave mainly in urine. Hemangeol’s infant study found a median half-life around 3.5 hours.

Inderal LA peaks at about 6 hours and has an apparent plasma half-life about 10 hours; its daily exposure differs from divided IR. Bedtime InnoPran XL has a delayed release lag and fasting steady-state peak about 12–14 hours after dosing; a high-fat meal shifts timing. These kinetics support each product’s instructions rather than a universal interchange rule.

Assess pressure/pulse and indication-specific response, including end-of-interval control after a formulation change. Report worsening dyspnea, weight gain, fainting, wheezing or serious skin reactions. Learn low-glucose symptoms that remain detectable despite beta blockade, and discuss fasting/vomiting promptly. Tell clinicians about propranolol before procedures.

Confirm weight, concentration and syringe mL markings; feed with each dose and maintain normal feeding. Parents need an explicit illness/fasting hold plan. Pale/blue skin, sweating, unusual sleepiness, poor feeding, breathing pauses or seizures may signal hypoglycemia: stop the medicine and get immediate care. Do not give anything by mouth to an unconscious infant.

Suspected overdose requires emergency evaluation, glucose/cardiac monitoring and supportive treatment. Bradycardia, hypotension, block, bronchospasm or hypoglycemia may occur. Propranolol is not significantly removed by dialysis. Do not attempt home emesis or improvise antidote doses.

Reviewed Amneal 10 mg IR tablet: orange, scored, PLIVA 467; 100-count NDC 69238-2077-1. Inderal LA 80 mg capsule is light blue, with three rings and INDERAL LA 80; 30-count NDC 62559-521-30. InnoPran XL 80 mg is gray/white, marked InnoPran XL, 80 and two bands; 30-count NDC 62559-590-30. Hemangeol current Eton 50 mL bottle NDC 71863-132-50 (120 mL: 71863-132-12).

Reviewed IR tablets: 10, 20, 40, 60 and 80 mg hydrochloride. Inderal LA capsules: 60, 80, 120 and 160 mg. InnoPran XL capsules: 80 and 120 mg. Hemangeol oral solution: 4.28 mg/mL hydrochloride, equivalent to 3.75 mg/mL propranolol base, supplied with a 5 mL oral syringe. Other liquids, injectable formulations and generics require their own labels.

IR: 20–25°C, light protection and a tight light-resistant container. Inderal LA: 20–25°C (excursions 15–30°C); protect from light, moisture, freezing and excessive heat. InnoPran XL: 25°C (excursions 15–30°C), tightly closed. Hemangeol: 20–25°C (excursions 15–30°C), original box; do not freeze or shake; discard opened bottle after 2 months and clean the oral syringe as directed.